Published January 25, 2005 | Version v1
Patent Open

Genetically engineered herpes virus for the treatment of cardiovascular disease

Contributors

Patent applicant:

Description

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.

Files

US6846670.pdf

Files (2.6 MB)

Name Size Download all
md5:4ce8c31ea2aa2b6be480a2f7b81e36f8
2.6 MB Preview Download

Additional details

Identifiers

Patent application number
US 99547501 A
Patent number
US 6846670 B2
Other
oai:uchicago.tind.io:9236

Dates

Patent filed
2001-11-28

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Radiation and Cellular Oncology, Surgery, Microbiology